DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment

 

Oncology Homepage

Baptist Hospital's Miami Cancer Institute awarded cancer research and education grant by IBA

ASCO expands TAPUR study enrollment after promising initial treatment outcomes seen

Delta4 Discover transmission detector approved for use by Varian Medical Systems on TrueBeam and Clinac systems

Intraoperative imaging systems market to reach $3.4 billion by 2024

Varian to showcase technologies for enhancing oncology care coordination at AONN+ Conference

United States proton therapy market is expected to reach nearly $1 billion, potentially $7 billion by 2025

Critical prostate cancer research funding saved

iCAD's Xoft clinical research selected as 'Best of ASTRO 2017'

Biop Medical launches cervical cancer diagnosis tech at Medica

Leading Belgian hospital OLVZ selects RayStation

Clinical trials and cutting-edge radiation oncology research to be featured at ASTRO’s Annual Meeting in San Diego

Press releases may be edited for formatting or style
The press program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO) will feature advances in cancer research, including reports from phase II and III clinical trials. Studies that examine innovative treatments, such as immunotherapy, mental health influences on cancer outcomes and optimal radiation dosing and sequencing, will also be presented at the largest meeting for the field of radiation oncology.

The meeting, which is expected to attract more than 11,000 attendees, will be held September 24 – 27, 2017, at the San Diego Convention Center. Researchers selected for the press program will share their findings in a series of news briefings held in room 24C and webcast live to registered press (register today!). The schedule is as follows:

Story Continues Below Advertisement

Streamline Your Radiology Workflow with RamSoft's PowerServer RIS/PACS

The PowerServer RIS/PACS is a single database application, essential to reducing redundant work, limiting manual data entry, and increasing consistency throughout healthcare practices. Click to learn how it will help you improve patient care and more.



The Science of Radiation Oncology: Innovative Approaches
Sunday, September 24, 1:00 – 2:00 p.m. Pacific time

“Consolidative radiotherapy for limited metastatic non-small cell lung cancer: A randomized phase II trial,” Puneeth Iyengar, MD, PhD, University of Texas Southwestern (Abstract LBA-3)
“Phase II 5-arm trial of ipilimumab plus lung or liver stereotactic radiation for patients with advanced malignancies,” James Welsh, MD, MD Anderson Cancer Center (Abstract LBA-5)
“Novel associations between the immune landscape of prostate cancer and post-operative radiation response,” Shuang (George) Zhao, MD, MSE, University of Michigan (Abstract 3)
[invited study to be confirmed]
Moderator: Brian Czito, MD, Duke University
Quality Care in Radiation Oncology: Refining Treatments
Monday, September 25, 11:00 a.m. – 12:00 p.m. Pacific time

“A phase III trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high-risk, early-stage endometrial cancer: A Gynecology Oncology Group study,” Marcus Randall, MD, FASTRO, University of Kentucky (Abstract LBA-1)
“Two-year results for MC1273, a phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiation in HPV+ oropharynx squamous cell carcinoma (OPSCC),” Daniel Ma, MD, Mayo Clinic (Abstract LBA-14)
“Hypofractionated radiation therapy after mastectomy for the treatment of high-risk breast cancer: Five-year follow-up result of a randomized trial,” Shulian Wang, MD, Chinese Academy of Medical Sciences and Peking Union Medical College (Abstract 5)
“Long-term results of RTOG 0617: A randomized phase III comparison of standard dose versus high dose conformal chemoradiotherapy +/- cetuximab for stage III NSCLC,” Jeffrey Bradley, MD, FASTRO, Washington University at St. Louis (Abstract 227)
  Pages: 1 - 2 - 3 >>

Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED